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patients with persistent asthma and chronic obstructive pulmonary disease 
(COPD) in the United Kingdom (UK). The potential cost benefit of improved inha-
lation technique, due to the innovative characteristics of the Spiromax® inhaler, 
was also investigated. Methods: The eligible adult patient population was 
based on current confirmed UK asthma and COPD diagnosis rates, with the pro-
portion of patients receiving FDCs based on market research data. The costs of 
Symbicort® Turbohaler® and scheduled and unscheduled health care events were 
taken from publically available UK sources. Frequency of poor inhalation tech-
nique with Symbicort® Turbohaler® and the associated increased risk of unsched-
uled health care events were taken from a large (n= 1,664) cross-sectional, Italian 
observational study. The estimated reduction in the proportion of patients with 
poor inhalation technique with DuoResp® Spiromax® compared with Symbicort® 
Turbohaler® was based on a conservative assumption. Results: An estimated 
409,445 adult patients used Symbicort® Turbohaler® annually in the UK and 
were therefore eligible for treatment with DuoResp® Spiromax®, with 178,108 of 
these exhibiting poor inhalation technique. Assuming a hypothetical uptake of 
DuoResp® Spiromax® reaching 25% in year 4 and 5 and its anticipated price, 
the model predicted drug cost savings totalling £36.09 million. Furthermore, 
39,266 unscheduled health care events could be avoided due to the predicted 
improvement in inhalation technique with DuoResp® Spiromax® com-
pared with Symbicort® Turbohaler®, resulting in further savings of £3.50 mil-
lion. ConClusions: DuoResp® Spiromax® is likely to offer budgetary savings 
compared with Symbicort® Turbohaler®, with further cost savings potentially 
resulting from improved inhalation technique.
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objeCtives: Chronic obstructive pulmonary disease (COPD) is an obstructive 
lung disease characterized by persistent airflow limitation. COPD has a signifi-
cant humanistic burden, representing the 5th leading cause of death in Portugal. 
The prevalence of Portuguese population with more than 40 years is 14.2%. COPD 
symptoms are similar to other respiratory diseases, making harder its diagnosis. 
Furthermore, it may result in inappropriate use of medication which is associated 
with an economic burden. This analysis aimed to estimate the economic impact 
of inappropriate use of inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) 
fixed-dosed combination in COPD patients. Methods: GOLD 2013 treatment algo-
rithm establish that ICS therapy should only be considered in high risk population 
(patients classified within GOLD groups C and D), presenting FEV1 < 50% (forced 
expiratory volume at 1 second) and/or 2 or more exacerbations per year. Based on 
a Delphi panel there are 1% of patients in group C and 29% in group D. According 
to ECLIPSE study, only 31% of patients in group C and 37% in group D are illegible 
for ICS therapy. Based on these assumptions, we estimated the overtreatment of 
ICS/LABA in Portugal according with local COPD prevalence and number of ICS/
LABA fixed-dosed combinations prescribed. It was also calculated the economic 
impact associated with therapy switch of over treated patients from ICS/LABA to 
glycopyrronium or indacaterol, according to GOLD 2013. Results: The treatment 
with ICS/LABA was estimated to be approximately 1.6 times greater than expected. 
Considering the number of patients over treated with ICS/LABA, the therapy switch 
for indacaterol or glycopyrronium would result in a potential saving of 4,314,390€ 
or 8,694,008€ , respectively. ConClusions: Optimization of COPD therapy in com-
pliance with GOLD guidelines would result in a better treatment for patients and 
potential savings, in a Portuguese National Health Service perspective.
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objeCtives: Chronic Obstructive Pulmonary Disease (COPD) is a prevalent disease 
with a significant economic burden to the UK National Health Service (NHS). NICE 
recommends maintenance treatment including inhaled bronchodilator medica-
tions such as long-acting muscarinic antagonists (LAMAs); tiotropium is the 
most widely used LAMA in the UK. The objective of this model was to quantify 
the budget impact to the NHS of switching patients from tiotropium to another 
LAMA, compared to remaining on tiotropium. Methods: Two matched patient 
groups were considered: patients who switched from tiotropium to another LAMA 
and patients who remained on tiotropium. The budget impact model was con-
ducted over a 3 month time horizon, with sensitivity analyses conducted over a 
12 month time horizon. Costs included were costs of medication; costs of patient 
identification and new inhaler training; and primary care resource use in the 
3 months following inhaler switch, priced according to PSSRU estimates. The 
number and duration of GP visits was estimated from the CPRD; a representative 
primary care patient database. Clinical efficacy endpoints were not included in 
the model. Results: Across the 3 month time horizon, patients who switched 
therapy incurred an increased incremental cost to the NHS of £77.10 per patient 
compared to patients who remained on tiotropium. Switching from tiotropium 
to other LAMA therapy also increased the NHS economic burden in the 12 month 
sensitivity analyses. Increased costs were driven by higher resource utilisation in 
terms of GP visits amongst switchers. ConClusions: Switching patients with 
COPD from tiotropium maintenance to another LAMA incurs an increased cost 
to the NHS. This is primarily due to a higher primary care resource use in the 3 
months following switch. This finding has implications for prescribing practice 
including GP workload and patient willingness to switch, hence patients remaining 
on tiotropium are cost-saving for the UK NHS
COPD cost was 3,290.7 [95%CI: 2539.9; 4051.2], but € 1161.0 [95% CI: 968.4; 1,353.6] 
in survivors and 6,158.9 [95% CI: 5,508.0; 6,809.8] in those who died, respectively 
(p< 0.001). The hospitalization cost impacted for 78.2% of the total annual cost in 
subjects who died, the absolute value being sixfold higher than in survivors. All 
economic components of cost were discriminant at three years, independently of 
gender. ConClusions: 1) several clinical and lung function variables contribute to 
predict mortality in COPD; 2) identification of COPD phenotypes is crucial, but mul-
tiple indices are required; 3) total annual cost proved the most sensitive predictor 
of mortality at three years; 4) annual cost is much easier and cheaper to obtain over 
twelve months; 5) data are supporting the high predicting value and the conveni-
ence of COPD “economic phenotyping”.
ReSPiRaToRy-RelaTeD DiSoRDeRS – cost Studies
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objeCtives: Fluticasone furoate/vilanterol (FF/VI) 92/22 mcg is a once-daily, fixed-
dose combination inhaled corticosteroid + bronchodilator licensed for the treatment 
of COPD in the UK. A budget impact model (BIM) was designed to explore the cost 
implications of prescribing FF/VI 92/22 in adult patients who continue to exacerbate 
or are currently receiving an off-license therapy versus alternative ICS/LABA thera-
pies, in line with clinical guidelines. Methods: A one-year BIM was constructed to 
explore the financial outcomes of prescribing FF/VI 92/22 as an alternative treatment 
option to currently prescribed therapies based on market shares. The BIM is based 
on UK prescription analysis, epidemiological and resource data. The model explores 
three routes for progressing patients: 1) exacerbating patients currently on LAMA or 
LABA monotherapy progressing onto ICS/LABA combination therapy; 2) exacerbat-
ing patients currently on ICS/LABA combination therapy progressing onto triple 
therapy; 3) patients currently on off-license therapies moved onto licensed COPD 
products. The model does not explore differences in patient outcomes, efficacy or 
safety; it explores drug acquisition cost alone. Results: The BIM estimates that 
the average health economy (e. g. clinical commissioning group; local health board) 
in the UK has 3066 COPD patients of whom 2138 continue to exacerbate or are 
prescribed off licence therapies. In year 1, progressing exacerbating patients onto 
alternative ICS/LABA combinations or triple therapy (50% implementation rate), or 
patients on off-license therapies onto licensed therapies (100% implementation rate) 
results in a budget impact of £156,498 compared with a budget impact of -£51,907 
if these patients are moved onto FF/VI 92/22. ConClusions: The introduction of 
FF/VI 92/22 in COPD has the potential to reduce the budget impact and total spend 
on combination ICS/LABA therapies by £208,405 in the average UK health economy 
compared to current patterns of prescribing.
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objeCtives: Fluticasone furoate/vilanterol (FF/VI) is a once-daily, fixed-dose combi-
nation inhaled corticosteroid + bronchodilator licensed for the treatment of asthma 
in the UK. A budget impact model (BIM) was designed to explore the cost implica-
tions of initiating FF/VI in patients ≥ 12 years not adequately controlled on ICS 
monotherapy (and as needed SABA) versus alternative ICS/LABA therapies, in line 
with BTS-SIGN guidelines. Methods: A one-year BIM was constructed to explore 
the financial outcomes of prescribing FF/VI as a treatment option in these dynamic 
patients. The BIM is based on UK epidemiological and resource data. It compares a 
scenario in which all eligible patients are treated with currently available ICS/LABA 
products based on market shares with a scenario in which FF/VI is introduced for 
uncontrolled patients eligible for step up onto an ICS/LABA combination therapy 
in line with clinical guidelines. The model does not explore differences in patient 
outcomes, efficacy or safety; it explores drug acquisition cost alone. Results: The 
BIM estimates that the average health economy (e. g. clinical commissioning group; 
local health board) in the UK has 7326 patient on ICS monotherapy of whom 3736 
are inadequately controlled and appropriate for step-up to an ICS/LABA combina-
tion therapy. In year 1, presuming a 50% implementation rate, stepping up these 
patients onto alternative ICS/LABA combinations at current usage rates results in 
a budget impact of £342,413 compared with a budget impact of £313,167 if these 
patients initiate FF/VI therapy. ConClusions: The introduction of FF/VI in asthma 
has the potential to reduce the budget impact and total spend on combination ICS/
LABA therapies by £29,246 in the average UK health economy compared to current 
patterns of prescribing.
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objeCtives: DuoResp® Spiromax® (budesonide + formoterol fumarate dihydrate) 
is a fixed-dose combination (FDC) of inhaled corticosteroid (ICS) + long-acting 
beta agonist (LABA) in a novel dry powder inhaler (DPI). An economic model was 
developed to assess the budget impact of using DuoResp® Spiromax® instead 
of Symbicort® Turbohaler® – a DPI delivering the same FDC – to manage adult 
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€ 617, € 65, € 1.707 and € 145 per patient, respectively. Budget impact analysis based on 
projected market shares of FF/VI, FP/S, and BUD/F revealed that introduction of FF/VI 
could save the national Sick Fund € 711,000 in the first three years. ConClusions: 
This model predicts that the introduction of FF/VI, a once daily FDC ICS/LABA, would 
reduce the overall costs of COPD treatment in Slovenia.
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objeCtives: It is estimated that the prevalence of moderate-to-severe SA (apnoea-
hypopnoea index > 15/h) is 10%. Approximately 11% of SA patients have comorbid 
COPD, which worsens sleep quality and desaturations. This study investigated the 
effects of PAP therapy on all-cause mortality and cost of illness (COI) in patients 
with SA and COPD in Germany. A statutory health insurance (SHI) perspective was 
taken. Methods: A total of > 4 million individuals covered by the SHI database 
were analysed (≈5% of the German SHI population). PAP therapy was initiated in 
4,068 patients with SA (PAP group). Propensity score matching was used to define a 
control group (CG) of 4,068 SA patients matched for age, sex, risk factors/aetiology, 
region and medication who received usual care (no PAP). Of these, 1,300 patients 
in the PAP group and 1,192 patients in the CG had comorbid COPD. This subgroup 
of patients was followed for 3 years after initiation of PAP therapy. Results: Total 
COI was higher in the PAP group versus CG in the first year of follow-up (€ 8,697 
vs € 6,999, p< 0.0001). However, during the second and third year the difference 
in COI between the PAP and CG was smaller (year 2: € 7,340 vs € 7,316, p< 0.0048; 
year 3: € 6,847 vs € 6,714, p< 0.001). PAP recipients had a significantly lower 3-year 
mortality rate compared with CG (8.2% vs 11.7%, p< 0.001; relative risk reduction 
30.1%). ConClusions: SA patients with COPD treated with PAP showed signifi-
cantly reduced mortality and morbidity. Total COI was higher in PAP recipients 
versus CG over the first 3 years of follow-up, but the difference between groups 
decreased over time. A follow-up period of ≥ 5 years may be required to show ben-
eficial economic outcomes in SA patients receiving PAP therapy.
PRS26
an analySiS of uS meDicaRe beneficiaRieS: buRDen of DiRecT meDical 
coSTS in PaTienTS wiTh iDioPaThic PulmonaRy fibRoSiS
Chen S.Y.1, Collard H.R.2, Yeh W.S.1, Li Q.3, Lee Y.C.3, Wang A.3, Raghu G.4
1Biogen Idec, Cambridge, MA, USA, 2University of California San Francisco, San Francisco, CA, 
USA, 3Evidera, Lexington, MA, USA, 4University of Washington, Seattle, WA, USA
objeCtives: In the US, more than half of patients with idiopathic pulmonary fibro-
sis (IPF) are covered by Medicare; yet published data on the economic burden that IPF 
imposes to this largest US payer are limited. The objective of this study was to com-
pare health care resource utilization (HRU) and costs between Medicare beneficiaries 
with IPF and matched non-IPF controls. Methods: Administrative claims from a 
5% random sample of Medicare beneficiaries (aged 65+) from years 2000 to 2011 
were analyzed. Incident IPF patients were identified based on ICD9-CM diagnosis 
codes, with at least one year enrollment before (pre-index) and after (post-index) 
the first diagnosis (index date). Up to 5 beneficiaries without IPF were matched to 
each IPF patient, based on age, gender, race, and region. Annual HRU and medical 
costs (excluding outpatient drug costs) during the pre-index and post-index peri-
ods were compared between IPF patients and the matched controls and univariate 
descriptive analyses were performed to compare the differences. Results: A total 
of 7,855 IPF patients were matched to 38,856 controls. During pre-index period, IPF 
patients had 2-3 folds higher risk of COPD, asthma and lung infections, 80% higher 
risk of hospitalization (28.8% vs. 15.8%), and higher total medical costs ($10,124 vs. 
$5,888) than matched controls (all p< 0.05). During post-index period, IPF patients 
had a higher risk of hospitalization (48.7% vs. 20.8%) and all other types of HRU 
with the total medical costs $11,955 higher than controls ($20,887 vs. $8,932) (all 
p< 0.05). Inpatient care accounted for 50% of total medical costs of IPF patients in 
both pre-index and post-index periods. ConClusions: In the US, IPF patients aged 
65 or older had a greater burden of comorbidity and incurred more HRU and medical 
costs than matched controls. Multidisciplinary team based approach and effective 
therapies are needed given the high unmet needs.
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objeCtives: To examine the economic burden and health care utilizations of 
patients diagnosed with chronic obstructive pulmonary disease (COPD) within the 
U. S. Medicare population. Methods: Patients diagnosed with COPD (International 
Classification of Disease 9th Revision Clinical Modification [ICD-9-CM] codes: 491, 
492, 496) were identified using the U. S. national Medicare claims dataset from 
01JAN2009 to 31DEC2011. The first diagnosis date was defined as the index date. A 
comparator group was created by identifying patients without a COPD diagnosis 
but of similar age, region, gender, index year and baseline Charlson Comorbidity 
Index scores. The index date for the comparator group was randomly chosen to 
reduce selection bias. One-year pre- and post-index continuous health plan enroll-
ment was required for both groups. A 1: 1 propensity score matching was used 
to compare follow-up health care costs and utilizations between the COPD and 
comparison cohorts, adjusted for baseline demographic and clinical characteris-
tics. Results: A total of 422,024 patients were identified for the COPD and compari-
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objeCtives: This study aimed to evaluate the economic burden of hospi-
talized pneumonia and its associated costs in the Brazilian Private Health 
System. Methods: An administrative claims database containing over 18 million 
lives was used to identify hospitalized pneumonia episodes, in all ages, between 
Oct/2010 and Dec/2013. Pneumonia episodes were identified using ICD-10 codes 
of A40.3, B95.3, G00.1, J13, J15, J15.0, J15.3, J15.4, J15.8, J15.9, J18, J18.0, J18.9, J20.2, 
P23.3. Pneumonia costs included were taxes and exchange, medicines, materials, 
medicinal gases, food, medical fees, exams, procedures and personal hygiene. The 
costs represent a total in the evaluated period for all causes and considering the 
total patients identified, average cost was calculated. Results: A total of 16,227 
pneumonia patients were identified with a total of 17,781 hospitalizations, repre-
senting an average of 1.1 hospitalizations per pneumonia patient in all ages. The 
aggregate costs for all inpatient treatment were BRL202,687,872.71 representing 
a total of 130,406 hospital days across the pneumonia patients. The average days 
for hospitalization per patient is 7.5 days. The average expenditure for the health 
insurance provider represents BRL12,490.78 per patient or BRL11,399.13, when 
evaluating per hospitalization. This translates to an average daily expenditure of 
BRL1,704.06 per patient or BRL1,555.13 per hospitalization. ConClusions: Costs 
related to pneumonia hospitalization are high and represents a large impact to 
the total budget spends in the private health care system. Given the significant 
economic burden associated with pneumonia, there is a need to better implement 
prevention strategies such as flu and pneumococcal vaccinations and smoking 
cessation.
PRS23
coST-minimizaTion anD buDgeT-imPacT analySiS of fixeD-DoSe icS/
laba combinaTion inhaleRS in The TReaTmenT of aSThma in Slovenia
Hren R.1, Trkman M.1, Stynes G.2
1GlaxoSmithKline d.o.o., družba za promet s farmacevtskimi izdelki, Ljubljana, Slovenia, 
2GlaxoSmithKline, Uxbridge, UK
objeCtives: To compare the expected costs and outcomes associated with the 
novel once-daily fixed-dose combination (FDC) of inhaled corticosteroid (ICS) and 
long-acting beta agonist (LABA) fluticasone furoate/vilanterol (FF/VI) against those 
expected with currently available FDC options, fluticasone propionate/salmeterol 
(FP/S), budesonide/formoterol (BUD/F) and beclometasone dipropionate/formoterol 
(BD/F), for asthma treatment in Slovenia. Methods: We developed a Markov model 
based on the results of seminal study GOAL (Gaining Optimal Asthma Control) that 
takes into account the complexity of asthma treatment and particularly accompa-
nying dose titration. Using available clinical evidence, we assumed that the clini-
cal efficacy and incidence of adverse events associated with a all four FDCs were 
similar. We compared FF/VI with other FDCs of ICS/LABA from the Slovenian payers’ 
perspective at the price levels determined by international reference pricing as of 
April 2014. We followed a cohort of 12,300 asthma patients over the time horizon of 
3 years with costs and outcoumes discounted at 3.5% per annum. Results: Model 
analysis showed that the expected three-year costs of FF/VI were lower than those 
of FP/S, BUD/F and BD/F by 13%, 40%, and 32%, respectively. The costs of treatment 
with FF/VI were lower than all other FDCs of ICS/LABA for patients who were previ-
ously treated with low/medium doses of ICSs (≤ 500 mg equivalent dose of BD) or 
high-doses of ICSs (> 500 mg and ≤ 1000 mg equivalent dose of BD). Budget impact 
analysis that was based on the current ICS/LABA market and projected market 
shares of FF/VI, FP/S, and BUD/F revealed that introduction of FF/VI could save 
the national Sick Fund € 863,000 over the first three years of use. ConClusions: 
Results of our model indicate that the introduction of the new once-daily FDC ICS/
LABA FF/VI could reduce the costs of asthma treatment in Slovenia over the first 
three years after introduction.
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objeCtives: To compare expected costs and health outcomes of the novel fixed-
dose combination (FDC) of inhaled corticosteroid (ICS) and long-acting beta agonist 
(LABA) fluticasone furoate/vilanterol (FF/VI) with currently available FDC options, 
fluticasone propionate/salmeterol (FP/S) and budesonide/formoterol (BUD/F), for 
chronic obstructive pulmonary disease (COPD) treatment in Slovenia. Methods: 
We developed a population-level Markov model based on the results of seminal 
TORCH (Towards a Revolution in COPD Health) study that accounts for disease 
progression of COPD and particularly the effects of changes in lung function and 
exacerbations. Using available clinical evidence, we assumed that all FDCs of ICS/
LABA were clinically equivalent. We compared FF/VI with two other FDCs of ICS/
LABA from the payers’ perspective at the Slovenian price levels determined by 
international reference pricing as of April 2014. We followed a cohort of 8,100 
Slovenian COPD patients for 20 years, with costs and outcomes discounted at 3.5% 
per annum. Results: The life expectancy predicted by the model was 8.74 years 
with 2.76 years spent in moderate COPD, 2.55 years in severe COPD, and 3.43 in 
very severe COPD. Model analysis showed that the expected three-year survival 
of the cohort was 91% and that the expected corresponding costs of FF/VI (€ 1.021 
per patient) were lower than those of FP/S (€ 1.535 per patient; +33% vs. FF/VI) and 
BUD/F (€ 1.260 per patient; +19% vs. FF/VI). Expected costs of maintenance, moderate 
exacerbations, severe exacerbations, and pneumonia were, for all treatment choices, 
